| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 01/21/2010 | WO2009146153A3 Manufacture, transport and delivery of material containing highly polarized nuclei |
| 01/21/2010 | WO2009140026A3 Renal function analysis method and apparatus |
| 01/21/2010 | WO2009129537A3 Magnetic microstructures for magnetic resonance imaging |
| 01/21/2010 | WO2009129220A3 Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
| 01/21/2010 | WO2009103741A3 Use of fsh receptor ligands for diagnosis and therapy of cancer |
| 01/21/2010 | WO2009026315A3 Use of carbon nanotube for drug delivery |
| 01/21/2010 | WO2004024097A9 Compositions and methods for the treatment of immune related diseases |
| 01/21/2010 | US20100016698 Integrated receiver for continuous analyte sensor |
| 01/21/2010 | US20100015152 Diagnostic and therapeutic methods |
| 01/21/2010 | US20100015058 Radiolabeled bbn-rgd heterodimers for cancer targeting |
| 01/21/2010 | US20100015057 Magnetoresonance preparations, device for individually selecting said preparations for increasing an organism life activity in actual environmental conditions |
| 01/21/2010 | US20100015056 Uranium-chelating peptides and uses thereof |
| 01/21/2010 | US20100015055 Pretreatment of a biological sample from an autoimmune disease subject |
| 01/21/2010 | US20100015054 Fluoro-substituted benzoxazole polymethine dyes |
| 01/21/2010 | US20100015050 Peg and targeting ligands on nanoparticle surface |
| 01/21/2010 | US20100015044 Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases |
| 01/21/2010 | US20100015041 Class of Supramolecular Drug Molecules and Methods of Identification and Use Thereof |
| 01/21/2010 | DE102008034020A1 Kontrastmittel verstärkte Strahlentherapie mit Hochleistungsröhren Contrast agent enhanced radiation therapy with high-performance tubes |
| 01/21/2010 | CA2731134A1 Novel method for measuring insulin resistance |
| 01/21/2010 | CA2730796A1 Aptamer against il-17 and use thereof |
| 01/21/2010 | CA2730734A1 Deuterated benzylbenzene derivatives and methods of use |
| 01/20/2010 | EP2144631A2 Multi-functional polyglutamate drug carriers |
| 01/20/2010 | EP1774332B1 Immune response assessment method |
| 01/20/2010 | CN101628120A Liver cancer targeting peptide/polyoxyethylene/diethylenetriaminepentaacetic acid hybrid ligand and synthesis method thereof |
| 01/20/2010 | CN101628119A Dermatophagoides pteronyssinus (Der p) allergen diagnostic reagent and preparation method thereof |
| 01/20/2010 | CN100581621C CNS chloride modulation and uses thereof |
| 01/20/2010 | CN100581589C Radioactively labelled amino acid analogues, their preparation and use |
| 01/20/2010 | CN100581588C Antisense oligonucleotide probe contrast agent marked by superparamagnetism iron oxide and production of the same |
| 01/20/2010 | CN100581458C Method for the spatially resolved determination of physical, chemical and biological properties or state variables |
| 01/19/2010 | CA2123492C Lymphoid antigen cd30 |
| 01/14/2010 | WO2010005697A2 18f-labelled three-and four-carbon acids for pet imaging |
| 01/14/2010 | WO2010004568A1 Device, method and kit for in vivo detection of a biomarker |
| 01/14/2010 | WO2010004060A1 Use of cilastatin for reducing nephrotoxicity of different compounds |
| 01/14/2010 | WO2009142754A4 Dendritic conjugates and methods of use |
| 01/14/2010 | WO2009136336A3 Medical microbubble generation |
| 01/14/2010 | WO2009115176A3 Magnetic nanoparticles and method for the production thereof |
| 01/14/2010 | WO2009110939A3 Drug delivery system for pharmaceuticals and radiation |
| 01/14/2010 | WO2008133709A3 Targeted split biomolecular conjugates for the treatment of diseases, malignancies and disorders, and methods of their production |
| 01/14/2010 | WO2008083312A3 Chemical linkers and cleavable substrates and conjugates thereof |
| 01/14/2010 | US20100011453 Model for muscular dystrophy and cardiomyopathy |
| 01/14/2010 | US20100011451 Phenotypic and genotypic differences of mva strains |
| 01/14/2010 | US20100010342 Tissue site markers for in vivo imaging |
| 01/14/2010 | US20100009363 RBP4 In Insulin sensitivity/resistance, diabetes, and obesity |
| 01/14/2010 | US20100008935 Method for identifying therapeutical targets in tumors, the use thereof and means for determining and targeting angiogenesis and hemostasis related to andenocarcinomas of the lung |
| 01/14/2010 | US20100008864 Aromatic multimers |
| 01/14/2010 | US20100008863 Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds |
| 01/14/2010 | US20100008862 Fluorescent magnetic nanoprobes, methods of making, and methods of use |
| 01/14/2010 | US20100008860 Color-marked oligosaccharides or polysaccharides |
| 01/14/2010 | US20100008859 Methods of treatment using ammonia-scavenging drugs |
| 01/14/2010 | US20100008858 Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules |
| 01/14/2010 | US20100008857 Novel hexatriene-beta-carbonyl compound |
| 01/14/2010 | US20100008855 Production and Use of Novel Peptide-Based Agents with Bispecific Antibodies |
| 01/14/2010 | US20100008854 Metal nanocomposite, preparation method and use thereof |
| 01/14/2010 | US20100008851 Anti-gd2 antibodies and methods and uses related thereto |
| 01/14/2010 | DE102008033662A1 Pharmacological dosage form, in the form of capsules or tablets, comprises two active magnetic parts that are arranged in unstable condition to each other and are biocompatible |
| 01/14/2010 | CA2730308A1 Peptides and their use as carriers into cancer cells |
| 01/14/2010 | CA2729949A1 Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| 01/14/2010 | CA2728343A1 18f-labelled three- and four-carbon acids for pet imaging |
| 01/13/2010 | EP2142927A1 A nanoporous particle with a retained target |
| 01/13/2010 | EP1427462B1 Method for inducing selectively suppressed immune response |
| 01/13/2010 | CN101626787A Diagnostic and therapeutic cyclooxygenase-2 binding ligands |
| 01/13/2010 | CN101623505A Diarrhetic shellfish poisoning okadaic acid OA mouse biological detection model |
| 01/13/2010 | CN101623504A Application of Evans Blue as solid tumor colorant |
| 01/13/2010 | CN100580080C Corona-virus-like particles comprising functionally deleted genomes |
| 01/13/2010 | CN100579583C Adducts between magnetic resonance shift reagents and substrates containing exchangeable protons for 'CEST' applications |
| 01/12/2010 | US7645441 Compositions and methods in cancer associated with altered expression of PRLR |
| 01/11/2010 | CA2641297A1 Pyrazine derivatives, methods of use, and methods for preparing same |
| 01/07/2010 | WO2010002479A1 Magnetic nanosensor compositions and bioanalytical assays therefor |
| 01/07/2010 | WO2009135001A3 Methods and compositions for regulating th2 and th17 responses |
| 01/07/2010 | WO2009128610A3 Cell labeling and imaging using multifunctional perfluorocarbon nanoemulsion |
| 01/07/2010 | WO2009117041A3 Use of pyrene to carry peptides across the blood brain barrier |
| 01/07/2010 | WO2009109569A3 Ester imaging agents |
| 01/07/2010 | WO2009063226A3 Methods relating to breathing disorders |
| 01/07/2010 | US20100003259 Antibodies that immunospecifically bind to b lymphocyte stimulator protein |
| 01/07/2010 | US20100003198 Antimicrobial Topical and Other Preparations Containing Fluorescent or Illumination Dye and Tracer Agents or Compounds |
| 01/07/2010 | US20100003197 Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof |
| 01/07/2010 | US20100003196 Fluorescent membrane intercalating probes and methods for their use |
| 01/07/2010 | US20100003195 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| 01/07/2010 | US20100003194 Inhibitor screening method and atopic dermatitis like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same |
| 01/07/2010 | US20100003193 Unit dosage of apadenoson |
| 01/07/2010 | US20100003189 Cancer biomarkers and methods of use thereof |
| 01/06/2010 | EP2140005A1 Antagonists of ligands and uses thereof |
| 01/06/2010 | EP2139524A1 Multivalent heterobifunctional polymers and methods of their use |
| 01/06/2010 | CN100577213C Non-invasive diagnostic imaging technology for mitochondria dysfunction using radiolabeled lipophilic salts |
| 01/05/2010 | US7642066 High throughput pharmaceutical screening using drosophila |
| 01/05/2010 | US7641643 Methods and compositions to treat myocardial conditions |
| 01/05/2010 | CA2592555C Oligonucleotidic sequences for the amplification of hiv-2 and siv-type retrovirus genome, and their applications for the in vitro diagnosis of infections due to these virus |
| 01/05/2010 | CA2438902C Manufacturing process to control particle size |
| 12/31/2009 | US20090328240 Genetically modified mice as predictors of immune response |
| 12/31/2009 | US20090328239 Blood vessel imaging and uses therefor |
| 12/31/2009 | US20090326510 Drug Delivery Methods and Systems |
| 12/31/2009 | US20090324603 Met fab and scfv fragments and methods of use |
| 12/31/2009 | US20090324503 Methods for detecting a mycobacterium tuberculosis infection |
| 12/31/2009 | US20090324502 Nasal Formulations of Insulin |
| 12/31/2009 | US20090324501 Vaccine Carrier |
| 12/31/2009 | US20090324500 Screen for inflammatory response modulators |
| 12/31/2009 | US20090324499 Vitamin-targeted imaging agents |
| 12/31/2009 | US20090324498 Method of measuring quantity of in-vivo substance by use of coherent anti-stokes raman scattered light |
| 12/31/2009 | US20090324494 Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance |
| 12/31/2009 | DE102008040042A1 Microparticle, useful in the diagnosis or therapy of e.g. tumors, metabolic diseases, comprises an aggregate from superparamagnetic nanoparticle, where the nanoparticle exists alone or in combination with an active agent, e.g. antibody |